| 000 | 01684 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250518101408.0 | ||
| 264 | 0 | _c20200514 | |
| 008 | 202005s 0 0 eng d | ||
| 022 | _a1536-5964 | ||
| 024 | 7 |
_a10.1097/MD.0000000000019907 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWang, Chun-Hsiang | |
| 245 | 0 | 0 |
_aConsolidation period of 18 months no better at promoting off-treatment durability in HBeAg-positive chronic hepatitis B patients with tenofovir disoproxil fumarate treatment than a 12-month period: A prospective randomized cohort study. _h[electronic resource] |
| 260 |
_bMedicine _cMay 2020 |
||
| 300 |
_ae19907 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAlanine Transaminase _xblood |
| 650 | 0 | 4 |
_aAntiviral Agents _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHepatitis B e Antigens _xblood |
| 650 | 0 | 4 |
_aHepatitis B virus _xdrug effects |
| 650 | 0 | 4 |
_aHepatitis B, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 |
_aSeroconversion _xdrug effects |
| 650 | 0 | 4 | _aSustained Virologic Response |
| 650 | 0 | 4 |
_aTenofovir _xadministration & dosage |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aChang, Kuo-Kuan | |
| 700 | 1 | _aLin, Ruey-Chang | |
| 700 | 1 | _aKuo, Ming-Jeng | |
| 700 | 1 | _aYang, Chi-Chieh | |
| 700 | 1 | _aTseng, Yuan-Tsung | |
| 773 | 0 |
_tMedicine _gvol. 99 _gno. 18 _gp. e19907 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/MD.0000000000019907 _zAvailable from publisher's website |
| 999 |
_c30923967 _d30923967 |
||